Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Thuerigen

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|January 23, 2018
Development of encorafenib for BRAF-mutated advanced melanomaPeter Koelblinger, Olaf Thuerigen, Reinhard Dummer
Nucleic Acids Research|February 19, 2005
Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarraysJoerg Schlingemann, Olaf Thuerigen, Carina Ittrich, et al.
International Journal of Cancer|December 7, 2007
The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastomaStefan Pfister, Stephen Rea, Mikko Taipale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancerOlaf Thuerigen, Andreas Schneeweiss, Grischa Toedt, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|January 23, 2018
Development of encorafenib for BRAF-mutated advanced melanomaPeter Koelblinger, Olaf Thuerigen, Reinhard Dummer
Nucleic Acids Research|February 19, 2005
Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarraysJoerg Schlingemann, Olaf Thuerigen, Carina Ittrich, et al.
International Journal of Cancer|December 7, 2007
The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastomaStefan Pfister, Stephen Rea, Mikko Taipale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancerOlaf Thuerigen, Andreas Schneeweiss, Grischa Toedt, et al.
Pageof 1